BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial. The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as an active anti-inflammatory and immunomodulatory agent. The Phase […]
